DZ Bank’s Alnylam Pharmaceuticals ALNY Stock Holding History

DZ Bank’s Portfolio ALNY Stock Details ALNY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-3,500	Closed	-$1.16M	–	1079
2026 Q1	$1.16M	Hold	3,500	–	–	﹤0.01%	705
2025 Q4	$1.39M	Hold	3,500	–	–	﹤0.01%	674
2025 Q3	$1.6M	Buy	+3,500	New	+$1.43M	﹤0.01%	654
2023 Q2	–	Sell	-39,316	Closed	-$7.88M	–	1023
2023 Q1	$7.88M	Buy	39,316 +3,941	+11%	+$828K	0.01%	395
2022 Q4	$8.41M	Hold	35,375	–	–	0.01%	370
2022 Q3	$7.08M	Buy	+35,375	New	+$6.75M	0.01%	379
2018 Q2	–	Sell	-9,650	Closed	-$1.15M	–	854
2018 Q1	$1.15M	Buy	+9,650	New	+$1.24M	﹤0.01%	634

Other funds holding ALNY

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

DZ Bank's ALNY Position: Q2 2026 in Review

DZ Bank sold out of Alnylam Pharmaceuticals (ALNY) in Q2 2026, closing a stake of 3,500 shares — an estimated $1.16M sold.

DZ Bank first reported a position in ALNY in Q1 2018 and held it in 7 quarters. The position peaked at $8.41M in Q4 2022. 784 funds tracked by Wall St. Rank hold ALNY as of Q2 2026.

DZ Bank reported no remaining Alnylam Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
DZ Bank sold 3,500 Alnylam Pharmaceuticals shares in Q2 2026, an estimated $1.16M.
DZ Bank first reported a position in Alnylam Pharmaceuticals in Q1 2018 and held it in 7 quarters.
DZ Bank's Alnylam Pharmaceuticals position peaked at $8.41M in Q4 2022.
784 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q2 2026.

Based on DZ Bank's 13F filing for Q2 2026, filed 14 Aug 2026.